USA – FDA issues draft guidance covering BIMO inspections
The US Food and Drug Administration (FDA) has issued two draft guidances on bioresearch monitoring (BIMO) inspections. The first covers information to assist the agency in planning these inspections, while the second covers best practices for communicating to the FDA before, during, or after an inspection. Both cover sponsors that have submitted new drug applications (NDAs), biologics license applications (BLAs), and supplements. More information on the Regulatory Focus Website.
Publication Details
- Journal
- Industrias Culturais (Universidade de Coimbra)
- Published
- 2024-10-19
- DOI
- https://doi.org/10.58079/12ja0
- Primary Topic
- Biosimilars and Bioanalytical Methods
- Type
- article
- Field-Weighted Citation Impact
- 0.00